News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III
H. Lundbeck A/S (LUN.CO) and Otsuka America Pharmaceutical, Inc. Release: Results Of Phase III Study Of Brexpiprazole In Adult Patients With Schizophrenia Published In American Journal Of Psychiatry 4/17/2015
MedDay Announces Its Pivotal Phase III Study Of MD1003 In Patients With Progressive Multiple Sclerosis Meets Primary Endpoint 4/17/2015
Investors Suddenly Interested in Synta (SNTA) and Its Upcoming Cancer Data 4/17/2015
Bristol-Myers Squibb (BMY) Soars After Halting Study Early As Opdivo Aces Test Again 4/17/2015
Full Data On Baxter International (BAX)’s Investigational Recombinant Treatment BAX 111 Supports Potential Role To Treat Von Willebrand Disease 4/17/2015
Ipsen (IPN.PA), Active Biotech AB (BTPC) Plummet As Prostate Cancer Drug Flunks Late-Stage Trial 4/16/2015
Pfizer (PFE) Beams As Cancer Drug Efficacy Stops Trial Early and Analysts Predict Game Changer 4/16/2015
Galena Biopharma  (GALE) Completes Over-Enrollment Of Neuvax (Nelipepimut-S) Phase 3 PRESENT Clinical Trial 4/16/2015
ZS Pharma (ZSPH) Announces Publications In Peer-Reviewed Medical Journals 4/16/2015
Peregrine Pharmaceuticals, Inc. (PPHM) Announces Three Abstracts Accepted For Presentation At American Association for Cancer Research 2015 Annual Meeting 4/16/2015
AEterna Zentaris (AEZS) Files Additional Patent Application To Strengthen IP Protection Of Zoptarelin Doxorubicin 4/16/2015
Adamis (ADMP) Pharmaceuticals Announces Positive Clinical Study Results For Its Albuterol (Salbutamol) HFA Product 4/16/2015
RegeneRx JV Retains Ora, Inc. To Conduct Phase 3 Trial For NK And Phase 2b/3 Trial For Dry Eye Syndrome In U.S. 4/16/2015
AbbVie (ABBV)'s Investigational Chronic Hepatitis C Treatment Granted Priority Review In Japan 4/16/2015
TRANSGENE (ENX:TNG): Agreement With FDA Announced For Special Protocol Assessment For Upcoming Phase 3 Pexa-Vec Trial In Advanced Liver Cancer 4/16/2015
SillaJen Announces Agreement With The FDA For A Special Protocol Assessment For Upcoming Phase 3 Pexa-Vec Trial In Advanced Liver Cancer 4/16/2015
Provectus Biopharmaceuticals Inc. Opens Patient Enrollment; Begins Phase 3 International FDA Comparative Clinical Trial Of PV-10 For Melanoma 4/16/2015
Roche (RHHBY) Says 11 Late-Stage Cancer Drugs Will Enter Trials in 2015 4/15/2015
Pfizer (PFE) Announces Paloma-3 Trial For Ibrance® (Palbociclib) Stopped Early Due To Efficacy Seen In Patients With Hr+, Her2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy 4/15/2015
Ocular Therapeutix (OCUL) Stock Caves After Eye Pain Drug Flunks Pivotal Trial 4/15/2015
Heart Metabolics Limited And FDA Reach Agreement On Special Protocol Assessment For Single Phase 3 Trial Of Perhexiline In Hypertrophic Cardiomyopathy 4/15/2015
CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot (DFU) And Ulcus Cruris (VLU) Indications 4/15/2015
Oncobiologics Inc. Announces Completion Of Clinical Dosing For bevacizumab (Avastin biosimilar) Candidate 4/15/2015
Phase III Trial Of The Merck & Co. (MRK) And NewLink Genetics Investigational Ebola Vaccine Initiated In Sierra Leone 4/15/2015
Heart Metabolics And FDA Reach Agreement On Special Protocol Assessment For Single Phase 3 Trial Of Perhexiline In Hypertrophic Cardiomyopathy 4/15/2015
Bayer HealthCare (BAY) Devises Phase III Plans for Top Prospect 4/14/2015
Soligenix (SNGX) Announces FDA Protocol Clearance Of Pivotal Phase 3 Clinical Trial Of SGX203 In Pediatric Crohn's Disease 4/14/2015
Catalyst Pharmaceuticals (CPRX) Announces Oral Presentation Of Firdapse Phase 3 Trial Data At American Academy of Neurology Annual Meeting (AAN) 4/14/2015
DBV Tech Nabs FDA Breakthrough Status for Peanut Allergy Patch 4/13/2015
AEterna Zentaris (AEZS) Announces Plans To Initiate Phase 3 Study Of Macrilen In AGHD Following Successful Meeting With FDA 4/13/2015
Angionetics Initial Equity Funding To Advance As Independent Company To Develop And Commercialize Phase 3 Generx Gene Therapy Product Candidate 4/13/2015
Neothetics Initiates Pivotal Phase 3 Clinical Trials For LIPO-202, The First Non-Invasive Injectable Drug Candidate For Reduction Of Subcutaneous Abdominal Fat 4/13/2015
UK’s Aintree University Hospital Joins CEL-SCI (CVM)’s Phase III Head And Neck Cancer Trial 4/13/2015
Onxeo Announces 6th Positive DSMB Recommendation For Livatag Relive Study In HCC 4/13/2015
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Shows That Health-Related Quality-Of-Life Is Higher In ABSSSI Patients Deemed Cured Vs Improved After End Of Treatment 4/10/2015
Cesca Therapeutics Management Provides Update On Clinical Trials For Critical Limb Ischemia ("CLI") And Acute Myocardial Infarction ("AMI") 4/10/2015
Adamas Pharmaceuticals (ADMS) Receives Orphan Drug Designation For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia Associated With Parkinson's Disease 4/10/2015
Lipocine Inc. (LPCN) Announces Presentation Of Additional LPCN 1021 Clinical Data At American Society Of Andrology 40th Annual Conference 4/10/2015
Horizon Pharma (HZNP) Receives FDA Fast Track Designation For ACTIMMUNE In The Treatment Of Friedreich's Ataxia 4/10/2015
Edge Therapeutics Banks $72.5 Million for Phase III Brain Hemorrhage Study 4/9/2015
BioLife Solutions, Inc. (BLFS.OB) CryoStor Cell Preservation Media Embedded In Cardio3 BioSciences' Phase III Clinical Trials Of C-Cure Cell Therapy For Congestive Heart Failure 4/9/2015
Exelixis, Inc. (EXEL)’s Cabozantinib Granted Fast Track Designation By FDA For Advanced Renal Cell Carcinoma 4/9/2015
Mesoblast Limited (MSB.AX) Phase 3 Program For Degenerative Disc Disease To Include European Sites After Positive Meeting With European Medicines Agency 4/8/2015
Portola Pharmaceuticals, Inc. Announces New Topline Data From Phase III Annexa-A Trial Part 2: Breakthrough Designated Andexanet Alfa 4/8/2015
GlycoMimetics, Inc. (GLYC) Provides Update On Pfizer (PFE)’s Plans To Initiate Phase 3 Trial With Rivipansel In Mid-2015 4/7/2015
Ocular Therapeutix (OCUL) Reports Topline Clinical Data For Its Second Phase 3 Clinical Trial Evaluating OTX-DP For The Treatment Of Post-Surgical Ocular Inflammation And Pain 4/7/2015
Taxus Cardium (CRXM) Announces Agreement With Dr. Reddy's Laboratories Ltd. (RDY) To Co-Develop, Market & Sell Generx Angiogenic Microvascular Gene Therapy In Certain International Markets 4/7/2015
MedDay Provides Update On Pioneering Pivotal Phase III Study Design In Progressive Multiple Sclerosis 4/7/2015
Cytori Therapeutics, Inc. (CYTX) Granted Orphan Drug Status For Cellular Therapeutic In European Union 4/7/2015
Charleston Laboratories, Inc. Completes Patient Enrollment In A Phase 3 Study Of Lead Product, CL-108 4/6/2015
Icon Bioscience Reports Successful Outcomes Of Phase 3 Study Of IBI-10090, A Novel Sustained Release Drug Being Developed To Treat Inflammation Associated With Cataract Surgery 4/6/2015
Flexion (FLXN) CEO Discusses Pipeline and Jobs 4/3/2015
Public Health Agency of Canada Release: Clinical Trials Prove Canada's VSV-EBOV Ebola Vaccine Safe And Effective 4/2/2015
Heron Therapeutics, Inc. (APPA) Reaches Target Patient Enrollment In MAGIC Phase 3 Study Of SUSTOL 4/2/2015
Thrasos Scores $21M to Complete Phase II THR-184, Expands Renal Portfolio 4/1/2015
Pivotal Pharmacokinetic Study Of Innocoll, Inc. (INNL)'s Xaracoll(R) Supports Use Of 300 Mg Dose For Phase 3 Clinical Studies In Post-Operative Pain 4/1/2015
Receptos (RCPT) Completes Enrollment Of RADIANCE Phase 3 Trial Of Ozanimod In Relapsing Multiple Sclerosis 4/1/2015
Nymox Pharmaceutical (NYMX) Announces Phase 3 BPH Studies 4/1/2015
CEL-SCI (CVM) Reports 3rd Consecutive Month Of Record Patient Enrollment In 2015 For Its Phase III Head And Neck Cancer Trial 4/1/2015
Kala Pharmaceuticals KPI-121 Meets All Primary Endpoints In Phase III For Cataract Surgery 4/1/2015
BioDelivery Sciences International (BDSI) Clonidine Topical Gel Fails Phase III, Shares Plunge 3/31/2015
PAION AG Announces Initiation Of U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Colonoscopy 3/31/2015
GW Pharmaceuticals (GWPH) Initiates First Phase 3 Pivotal Trial For Epidiolex In Dravet Syndrome 3/31/2015
Argos Therapeutics, Inc. (ARGS) Reports Fourth Quarter And Year-End 2014 Financial Results 3/31/2015
Achaogen (AKAO) Announces Webcast Providing Update On Development Plan For Plazomicin 3/31/2015
Intra-Cellular Therapies, Inc. Presents The ITI-007 Clinical Development Program At The 15th International Congress On Schizophrenia Research 3/31/2015
Emmaus Life Sciences To Present Phase 3 Sickle Cell Disease Clinical Trial Data 3/31/2015
Can-Fite BioPharma (CFBI) PhII/III: CF101 Did Not Achieve Primary Endpoint 3/30/2015
GENFIT (ALGFT)'s GFT505 Misses Target in Phase IIB But Hopes to Proceed to Phase III 3/30/2015
Can-Fite BioPharma (CFBI) Files 2014 Annual Report On Form 20-F 3/30/2015
Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3/30/2015
Morphotek Inc. Announces Initiation Of Farletuzumab Study In Patients With First-Relapsed, Platinum-Sensitive Ovarian Cancer With Low Levels Of The Immunosuppressive CA125 Tumor Antigen 3/30/2015
Janssen Research & Development Release: New Study Published In JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time To Relapse In Patients With Schizophrenia 3/30/2015
Sigma-Tau Pharmaceuticals Receives Orphan Drug Designation For EZN-2279 For Treatment Of Adenosine Deaminase--Deficient Severe Combined Immunodeficiency Disease 3/30/2015
Teva (TEVA) Reinforces Leadership Position In CNS With Acquisition Of Auspex Pharmaceuticals (ASPX) 3/30/2015
Cardio3 BioSciences Successfully Completes Futility Analysis Of Lead Cardiac Cell Therapy, C-Cure(R) 3/30/2015
Alnylam (ALNY) Initiates ENDEAVOUR Phase 3 Clinical Trial With Revusiran 3/27/2015
European Medicines Agency Release: Accelerated Assessment Fast-Tracks Lenvima To Benefit Patients With Thyroid Cancer 3/27/2015
NephroGenex (NRX) Announces Data On Acute Kidney Injury At National Kidney Foundation 2015 Spring Clinical Meetings 3/27/2015
Northwest Biotherapeutics (NWBO) Reports Promising Survival Data In 51 Gbm Patients Treated With Dcvax-L 3/27/2015
Galderma Announces Positive Outcome Of European Decentralised Procedure For Approval Of Soolantra (Ivermectin) Cream 10mg/G For Rosacea Patients 3/27/2015
Results Of Auspex Pharmaceuticals (ASPX)' Phase 3 Registration Trial Of SD-809 To Be Presented At American Academy of Neurology Annual Meeting 3/27/2015
Relypsa (RLYP) Presents Sub-Group Analysis From Phase 3 Study Of Patiromer FOS In Patients With Advanced Chronic Kidney Disease At 2015 National Kidney Foundation Spring Clinical Meeting 3/27/2015
Merck & Co. (MRK) Study Halted on Positive Phase III Data 3/26/2015
pSivida Corp (PSDV) Completes Targeted Enrollment Of Phase III Trial Of Medidur For Posterior Uveitis 3/26/2015
Novavax, Inc. (NVAX) Prices Public Offering Of Common Stock 3/26/2015
Cardio3 BioSciences Reports 2014 Financial And Operating Results 3/26/2015
Neothetics Reports Fourth Quarter and Full Year 2014 Financial Results 3/26/2015
Onxeo Expands Livatag International Phase III Clinical Trial "Relive" To 3 New Countries 3/26/2015
Lexicon Pharmaceuticals, Inc. (LXRX) Announces First Patient Screened In Pivotal Phase 3 Clinical Trial Of Sotagliflozin 3/25/2015
Vericel (ASTM) Reports Three-Year Follow-Up Results From Phase 3 SUMMIT Extension Study Of MACI Implant 3/25/2015
TRANSGENE (ENX:TNG) Reports 2014 Financial Results And Outlines Promising Clinical Pipeline 3/25/2015
NephroGenex (NRX) Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2014 3/25/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Initial Payment For RGN-259 U.S. License To ReGenTree Joint Venture 3/25/2015
ThromboGenics NV (TBGNF) Announces Positive Topline Results From OASIS Study 3/24/2015
Mast Therapeutics (MSTX) Reports Fourth Quarter And Full Year 2014 Financial Results 3/24/2015
Aerie Pharmaceuticals, Inc. (AERI) Completes Enrollment In Second Phase 3 Registration Trial (“Rocket 2”) Of Rhopressa, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma 3/24/2015
La Jolla Pharmaceutical Company (LJPC) Announces Initiation Of Phase III Clinical Trial Of LJPC-501 In Catecholamine-Resistant Hypotension 3/24/2015
LFB S.A. Receives Go Ahead From Data Monitoring Committee To Expand The Global PERSEPT Phase 3 Program Of LR769 In Hemophilia A Or B Patients With Inhibitors 3/24/2015
Can-Fite BioPharma (CFBI) Signs Multi-Million Dollar Distribution Agreement For CF101 In Canada With Cipher Pharmaceuticals (DND.TO) 3/23/2015
Cipher Pharmaceuticals (DND.TO) Acquires Canadian Rights To Novel Treatment For Psoriasis And Rheumatoid Arthritis 3/23/2015
Novartis AG (NVS) Presents Cosentyx Two-Year Efficacy And Safety Data Showing Sustainable Effect In Psoriasis Patients 3/23/2015
EXCLUSIVE: Resverlogix Corporation (RVX.TO) CEO Says Experimental Cardiac Drug Holds High Hopes, As Biotech Booms 3/20/2015
AbbVie (ABBV) Elated as Pharmacyclics (PCYC)'s Imbruvica Shines in Combo Trial 3/20/2015
Nektar Therapeutics (NKTR) Cancer Drug Improves Survival But Misses Primary Endpoint, As Watchers Worry 3/20/2015
Intarcia Therapeutics, Inc. And Numab AG Sign Multi-Asset Collaboration To Develop Once-Yearly Therapies In Diabetes, Obesity, and Autoimmune Indications 3/20/2015
Anthera, Inc. Announces $3 Million Research Award From Cystic Fibrosis Foundation Therapeutics, Inc. For Development Of Sollpura - A Novel Enzyme Therapy 3/20/2015
Amgen (AMGN) Submits Application For Investigational LDL Cholesterol-Lowering Medication Repatha (evolocumab) In Japan 3/20/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Chooses PharmaCell As Contract Manufacturing Partner For Its Phase III Program In Europe 3/20/2015
Galderma Laboratories Announces Positive Phase 3 Trial Results Of Investigational Adapalene 0.3%/Benzoyl Peroxide 2.5% (0.3% A/BPO) For The Treatment Of Acne 3/20/2015
New Novartis AG (NVS) Data Show More Cosentyx-Treated Psoriasis Patients Achieved Clear Or Almost Clear Skin (PASI 90) Compared To Stelara 3/20/2015
Celgene (CELG) Release: Oral Otezla (Apremilast) Long-Term Safety And Efficacy Data In Patients With Moderate To Severe Plaque Psoriasis Presented At American Academy of Dermatology 3/20/2015
Celgene (CELG) Release: Positive Results From Phase III Study Evaluating Oral Otezla (Apremilast) Or Injectable Etanercept Versus Placebo In Patients With Moderate To Severe Plaque Psoriasis Presented At American Academy of Dermatology 3/20/2015
Sanofi (SAN.PA) Test Shows Lixisenatide Doesn't Up Cardiovascular Risk 3/19/2015
ImmunoCellular Therapeutics, Ltd (IMUC) Establishes Manufacturing Agreement With Pharmacell B.V. For European Production Of ICT-107 For Phase 3 Registration Trial 3/19/2015
PTC Therapeutics (PTCT) And University of Pennsylvania Collaborate On Orphan Disease Research 3/19/2015
ZS Pharma (ZSPH) To Present Data From Phase 3 Trials Of ZS-9 In Presentations At The National Kidney Foundation 2015 Spring Clinical Meetings 3/19/2015
Scioderm Initiates Phase 3 Registration Trial Of Zorblisatm (SD-101), A Novel Topical Therapy For Patients With Epidermolysis Bullosa 3/19/2015
AstraZeneca PLC (AZN) Two-in-One Lung Drug Succeeds in Phase III Trial 3/19/2015
New Cholesterol Drugs From Amgen (AMGN), Sanofi (SAN.PA), Regeneron (REGN) Cut Heart Risks in Half But Questions Remain 3/18/2015
AstraZeneca PLC (AZN) Announces Positive Phase III Top-Line Results For PT003 From PINNACLE 1 And PINNACLE 2 Studies In COPD 3/18/2015
Lexicon Pharmaceuticals, Inc. (LXRX) And Ipsen (IPN.PA) Expand Their Licensing And Commercialization Agreement For Telotristat Etiprate To Include Canada 3/18/2015
Tenax Therapeutics (TENX) Announces Third Quarter Fiscal Year 2015 Financial Results 3/18/2015
Biogen Idec (BIIB) Will Be Hiring in R&D After Around 20 Employees Leave Following Review 3/17/2015
Pharmacyclics (PCYC) Release: Independent Data Monitoring Committee Unanimously Recommends Unblinding Of IMBRUVICA (Ibrutinib) Phase III Combination HELIOS Trial Based On Interim Analysis Showing Significant Improvement In Progression-Free Survival In Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma 3/17/2015
Sinovac Biotech Ltd. (SVA) Provides Updates On Pipeline Vaccines 3/17/2015
Collegium To Present Xtampza ER Pivotal Phase III Data At The 2015 American Academy Of Pain Medicine Annual Meeting 3/17/2015
The Lancet Publishes CSL Behring's Kcentra Phase III Data 3/17/2015
QIAGEN N.V. (QGEN) Expands Leadership In Liquid Biopsies With New Circulating Tumor Cell Technology For Development Of Companion Diagnostics 3/17/2015
Anavex (AVXL) To Participate In Phase 3 Clinical Trials Panel At AD/PD 2015 3/17/2015
Sanofi (SAN.PA), Regeneron (REGN): 18-Month Results Of ODYSSEY LONG TERM Trial With Praluent (Alirocumab) Published In The New England Journal of Medicine 3/16/2015
Amgen (AMGN) Release: New Detailed Data From Phase 3 Study Show Amgen's Repatha (Evolocumab) In Combination With Statins Reduced LDL-C By 67-76 Percent Compared To Placebo In Japanese Patients With High Cardiovascular Risk And High Cholesterol 3/16/2015
Amgen (AMGN) Publishes Safety Analysis Of Investigational Cholesterol-Lowering Medication Repatha (evolocumab) In The The New England Journal of Medicine 3/16/2015
AcelRx (ACRX) Announces Initiation Of Pivotal Phase 3 Trial For ARX-04 3/16/2015
Anthera Pharmaceuticals, Inc. (ANTH) Announces Completion Of Interim Analysis From Phase 3 Trial With Blisibimod For IgA Nephropathy 3/16/2015
Yisheng Biopharma Co., Ltd. Release: A New Therapeutic Vaccine Successfully Developed Against Rabies 3/16/2015
Provectus Biopharmaceuticals Inc.’ Amended Protocol Of PV-10 For Phase III Study As Treatment For Melanoma Now Available Online 3/16/2015
Mezzion Pharma Commits To Phase 3 Clinical Trials Of Udenafil In Adolescents With A Single Functional Ventricle That Have Undergone Fontan Surgical Palliation 3/16/2015
Medivir AB (MVRBF): New Data On Simeprevir Presented At The Conference Of The Asian Pacific Association For The Study Of The Liver 3/16/2015
Baxter BioScience Corporation (BAX) Announces Positive Phase III Results For BAX 817, Investigational Recombinant Treatment For Hemophila A And B Patients With Inhibitors 3/13/2015
Cytokinetics, Inc. (CYTK) Announces Completion Of Enrollment In COSMIC-HF 3/13/2015
Charleston Laboratories, Inc. And Daiichi Sankyo (4568.t) Announce Completion Of A Pharmacokinetics Study On CL-108 3/12/2015
Provectus Biopharmaceuticals Inc. Updates Market On Business Developments 3/12/2015
Cynapsus Therapeutics (CYNAF) Provides Clinical And Regulatory Update For APL-130277 For The Acute Rescue Of OFF Motor Symptoms Of Parkinson’s Disease 3/12/2015
XBiotech Launches Website And Call Center To Inform Cancer Patients About New Xilonix Therapy And Phase III Clinical Study 3/12/2015
At a Top Notch Facility in SoCal, Amgen (AMGN) Works on Perfecting and Cranking Out Biosimilars 3/11/2015
PharmaEssentia And AOP Orphan Announce Completion Of Recruitment Of Pivotal Phase III Trial PROUD-PV 3/11/2015
Dr. Anita J. Chawla Joins CytRx Corporation (CYTR) Board Of Directors To Add Additional Drug Commercialization Expertise In Oncology 3/11/2015
Takeda (TKPYY) Announces Publication In The Lancet Of A Post Hoc Analysis Of Data From The EXAMINE Cardiovascular Safety Outcomes Trial 3/10/2015
Auris Medical AG (EARS) Announces Completion Of Interim Analysis In Post-Acute Tinnitus Stratum Of TACTT3 Trial With AM-101 3/10/2015
Ocular Therapeutix, Inc. (OCUL) Reports Positive Topline Clinical Data For The First Of Two Phase 3 Clinical Trials Evaluating OTX-DP For The Treatment Of Post-Surgical Ocular Inflammation And Pain 3/10/2015
Lexicon Pharmaceuticals, Inc. (LXRX) Completes Enrollment In Pivotal Phase 3 Clinical Trial Of Telotristat Etiprate 3/9/2015
Novo Nordisk A/S (NVO) Release: New Data In Adults With Obesity Or Who Are Overweight With Comorbidities Losing At Least 5% Body Weight With Saxenda (liraglutide [rDNA origin] injection) Showed Improvement In Blood Glucose, CV Risk Factors And Quality Of Life Outcomes 3/9/2015
ContraVir Pharmaceuticals To Initiate Pivotal Phase 3 Study Of FV-100 For Prevention Of Shingles-Associated PHN 3/9/2015
CTI BioPharma, Baxter International (BAX)'s Blood Cancer Drug Meets Main Goal in Late-Stage Trial 3/9/2015
Opexa Therapeutics (OPXA) Amends Agreement With Merck Serono And Receives Additional $3 Million Payment To Support Ongoing Development Of Tcelna For Multiple Sclerosis 3/9/2015
R-Tech Ueno: The End Of A Phase 3 Clinical Study And Preliminary Findings From A Phase 3 Of Unoprostone (Development Code UF-021) For Treatment Of Retinitis Pigmentosa 3/9/2015
Trimel Pharmaceuticals (TRL.TO) Announces Natesto Abstract Presentation At The 2015 Endocrine Society Annual Meeting 3/9/2015
BioLineRx Ltd. Announces Underwritten Public Offering Of Its American Depositary Shares 3/6/2015
AEterna Zentaris (AEZS) Announces Pricing Of US$37 Million Public Offering Of Common Shares And Warrants 3/6/2015
CytoTools: European Trials On Diabetic Foot And Ulcus Cruris (Leg Ulcers) On Schedule - Delay In The Market Approval For The Wound Healing Agent Dermapro In India 3/6/2015
Orexigen (OREX)'s Failure to Keep a Lid on it Prompts the FDA to Force a Second Study 3/6/2015
EXCLUSIVE: Experimental Cancer Drug From Oncoceutics Could Be Fast-Tracked, Says Exec 3/6/2015
Catalyst Pharmaceuticals (CPRX) Announces FDA Orphan Drug Designation Of Firdapse For Treatment Of Congenital Myasthenic Syndromes 3/5/2015
AOP Orphan Pharmaceuticals AG Announces Progress Of Pivotal Phase 3 Trial PROUD-PV Applying Ropeginterferon ALFA 2B, A Novel, Long-Acting, Mono-Pegylated Interferon For Treatment Of Polycythemia Vera 3/5/2015
Chiasma Announces New Data For Investigational Octreotide Capsules 3/5/2015
Lexicon Pharmaceuticals, Inc. (LXRX) Provides Clinical Pipeline Update And Reports 2014 Fourth Quarter And Full Year Financial Results 3/4/2015
Keryx Biopharmaceuticals (KERX) Announces Publication Of Auryxia (Ferric Citrate) Analysis In Journal Of The American Society Of Nephrology 3/4/2015
CorMedix (CRMD) Provides Multiple Strategic Business Updates 3/4/2015
Drug Approved In Pivotal Studies Using DSG, Inc.’s Fully Electronic Source Data 3/3/2015
Delcath Systems, Inc. (DCTH) Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal 3/3/2015
Amgen (AMGN) Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 3/3/2015
CEL-SCI (CVM) Reports 2nd Consecutive Month Of Record Patient Enrollment In 2015 For Its Phase III Head And Neck Cancer Trial 3/3/2015
Gilead (GILD)'s Harvoni Achieves 96% Cure Rate in Patients With Hepatitis C and HIV 3/2/2015
Otsuka Pharmaceutical Co., Ltd. Release: First-Ever Treatment Approved In Canada For Adults Living With ADPKD, A Life-Threatening Kidney Disease 3/2/2015
Portola Pharmaceuticals, Inc. Announces Full Results From Positive Phase 3 ANNEXA-R Study Demonstrating That Andexanet Alfa Rapidly And Significantly Reversed Anticoagulant Effect Of Factor Xa Inhibitor XARELTO 3/2/2015
Dynavax Technologies Corporation (DVAX) Announces Second Independent DSMB Recommendation To Continue Phase 3 Study Of HEPLISAV-B 3/2/2015
Amgen (AMGN) Release: Phase 3 Head-To-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis (Carfilzomib) Over Velcade (Bortezomib) In Patients With Relapsed Multiple Myeloma 3/2/2015
CEL-SCI (CVM) Completes Key Milestone With Clearance To Conduct Phase 3 Trial In 21 Countries 3/2/2015
Isis Pharmaceuticals, Inc. (ISIS) Earns $15 Million From GlaxoSmithKline (GSK) for Advancing ISIS-TTR Rx 3/2/2015
Amgen (AMGN)'s Hormone-Imbalance Drug AMG 416 Shows Positive Results in Phase 3 Study 2/27/2015
Gilead (GILD) Announces SVR12 Rates From Phase III Study Evaluating Harvoni For The Treatment Of Chronic Hepatitis C In Patients Co-Infected With HIV 2/27/2015
Argos Therapeutics, Inc. (ARGS) Announces Update On Phase 3 ADAPT Trial To Be Presented During 2015 ASCO Genitourinary Cancers Symposium 2/27/2015
Amgen (AMGN) Receives Positive CHMP Opinion For Use Of Vectibix (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Advanced Colorectal Cancer 2/27/2015
Biogen Idec (BIIB) And Swedish Orphan Biovitrum Announce Positive Top-Line Efficacy And Safety Results From Phase 3 ALPROLIX Pediatric Study 2/27/2015
Gilead (GILD) Announces Phase 3 Results For Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF) 2/27/2015
Bristol-Myers Squibb (BMY) Release: ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected With HIV After Ribavirin-Free Investigational 12-Week Regimen Of Daclatasvir And Sofosbuvir 2/27/2015
TherapeuticsMD, Inc.  (TXMD) Has "Multiple Catalysts" in 2015/16 As Products Develop, Says Cowen and Company 2/26/2015
ABIVAX Recruits First Patient In A Pivotal Phase 2b/3 Clinical Trial With ABX203, A Novel Immunotherapy Against Chronic Hepatitis B 2/26/2015
Chimerix (CMRX) Provides Update On Anticipated SUPPRESS Enrollment 2/26/2015
Portola Pharmaceuticals, Inc. Receives FDA Orphan Drug Designation For Andexanet Alfa, Its Breakthrough-Designated Factor Xa Inhibitor Antidote 2/26/2015
Gradalis Inc. Announces Initiation Of A Phase 3 Registration Study For Vigil In Ovarian Cancer 2/26/2015
Bristol-Myers Squibb (BMY) Release: Study Of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results In Preventing Viral Replication Via Different Mechanism Of Action Than Current Therapies 2/26/2015
Amgen (AMGN) Announces Positive Results From Head-To-Head Study Comparing The Efficacy And Safety Of AMG 416 With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis 2/26/2015
Eisai Inc. (ESALF.PK) Release: Topline Results Of Phase 3 Trial Show Eribulin Mesylate Injection Meets Primary Endpoint Of Overall Survival In Advanced Soft Tissue Sarcoma 2/25/2015
Dipexium Pharmaceuticals (DPRX) Passes 25% Enrollment In Locilex Pivotal Phase 3 Clinical Trials 2/25/2015
Nektar Therapeutics (CA) (NKTR) Announces Start Of Phase 3 SUMMIT-07 Study Of NKTR-181 In Patients With Chronic Low Back Pain 2/25/2015
Sunovion Pharmaceuticals Inc. Announces Initiation Of Phase 3 Clinical Trial Program For SUN-101/Eflow (Glycopyrrolate) In Moderate-To-Very Severe Chronic Obstructive Pulmonary Disease (COPD) 2/25/2015
Bristol-Myers Squibb (BMY) Release: 48-Week Analysis Of Investigational HIV-1 Attachment Inhibitor Paves Way For Phase III Trial Initiation 2/25/2015
Antares Pharma, Inc. (ATRS) Announces Positive Top-Line Pharmacokinetic Results From The Quickshot Phase 3 Study In Testosterone Deficient Men 2/25/2015



//-->